Device type · NYI
Classifier, Prognostic, Recurrence Risk Assessment, Rna Gene Expression, Breast Cancer
Last checked: Nov 20, 2026Source: openFDAMethods & limitations
Product code
NYI
Pathology
Device class
Class II
FDA decisions since 2015
3
510(k), De Novo and PMA
Adverse event reports
0
Received Nov 1, 2025 to Nov 20, 2026
How FDA classifies it
- Device type
- Classifier, Prognostic, Recurrence Risk Assessment, Rna Gene Expression, Breast Cancer
- Product code
- NYI
- Device class
- Class II
- Review panel
- Pathology
- Regulation
- 21 CFR 866.6040
- Specialty
- Laboratory Medicine & Pathology
- FDA record
- Classification database entry for NYI
Latest FDA decisions
- MammaPrint FFPE NGS Kit510(k)
K210973 · Decided Sep 8, 2022 · 526 days after receipt
Device type: Classifier, Prognostic, Recurrence Risk Assessment, Rna Gene Expression, Breast Cancer (NYI) · Laboratory Medicine & Pathology
2 more FDA decisions with a free account
Reports received
0
Received Nov 1, 2025 to Nov 20, 2026
Malfunction reports
0
Injury reports
0
Death reports
0
Adverse event reports received per month
By the date FDA received each report, stacked by event type. The newest month is incomplete.
No reports to chart for this view.
Manufacturers named most often
Last 12 months. Bigger sellers get more reports. This is not a ranking of safety.
No manufacturers to rank.
Device problems as coded
Last 12 months. FDA's terms. A report can carry several.
No device problems coded.
Patient problems as coded
Last 12 months. FDA's terms. A report can carry several.
No patient problems coded.
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-1321-2010 · Started Mar 3, 2010 · Posted by FDA Apr 12, 2010
Reason given: Over a period of about 6 months in about 15% of results provided Agendia has been "over reporting" the chance of metastasis risk being 29% risk of recurrence instead of 10% risk. This over reporting of risk did not cause direct injury to patients. However, if used by physicians as the sole basis for decision-making,...
Cause as FDA categorized it: Other
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.